Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 4

Different systemic therapies in HER2-positive patients.

HER2-positive patients (year of diagnosis: 2006–2012)
	Trastuzumab + CHT + AHT	Trastuzumab + CHT	CHT + AHT	CHT	AHT	No adjuvant therapy	Total
2006	27 (24.8%)	14 (12.8%)	9 (8.3%)	9 (8.3%)	40 (36.7%)	10 (9.2%)	109 (100%)
2007	30 (32.6%)	22 (23.9%)	6 (6.5%)	1 (1.1%)	21 (22.8%)	12 (13.0%)	92 (100%)
2008	31 (34.8%)	21 (23.6%)	6 (6.7%)	4 (4.5%)	16 (18.0%)	11 (12.4%)	89 (100%)
2009	45 (40.2%)	14 (12.5%)	9 (8.0%)	4 (3.6%)	24 (21.4%)	16 (14.3%)	112 (100%)
2010	44 (39.3%)	19 (17.0%)	9 (8.0%)	3 (2.7%)	18 (16.1%)	19 (17.0%)	112 (100%)
2011	29 (45.3%)	13 (20.3%)	4 (6.2%)	3 (4.7%)	10 (15.6%)	5 (7.8%)	64 (100%)
2012	15 (22.4%)	9 (13.4%)	1 (1.5%)	9 (13.4%)	9 (13.4%)	24 (35.8%)	67 (100%)
Total	221 (34.3%)	112 (17.4%)	44 (6.8%)	33 (5.1%)	138 (21.4%)	97 (15.0%)	645 (100%)